(ALLWEGENE DIAGNOSTICS), an important member of the ALLWEGENE (ALLWEGENE) group, opened in the Tianjin free trade zone (Airport Economic Zone) in December 23, 2017. Adhering to the vision of "genetic technology for the public", we adhere to the concept of "technology based, rigorous, reliable, delicate service, and patient first", and is committed to the rapid transformation of the most advanced and reliable international technology (Multi-Omics) in medical science. At the same time, combined with its technological advantages over many years, genetic testing services can be widely accepted by the public. In order to achieve the goal of "reducing birth defects, improving precise medication, strengthening disease prevention and control, and helping early screening of tumors".
Ovison medicine is committed to becoming the first choice for the overall solution of precision medicine in China, based on the global leading biological information research and technology transformation application platform of the other important group of the group, Ovison Technology (ALLWEGENE TECHNOLOGIES), which is built in line with ISO 9001:2015 and ISO 15189:2012. Improve the medical genetic testing production management system and quality control system. At the same time, the GENE BANK, which is the leading international management standard, has been set up to provide the most professional, rigorous and reliable medical service for the public.
Ovison's medical headquarters is located in Tianjin. Branches and offices are set up in Beijing, Jiangsu, Hubei, Shaanxi, Guizhou, Fujian, Guangdong and other places, and a R & D center in Rutgers University, New Jersey, United States. In collaboration with Nebula AI, Montreal, Canada, the "third generation of artificial intelligence block chain" technology is used in medicine to make the subjects' data, data and reports more secure and reliable.
The team is composed of highly educated and highly educated people with rich research and management experience in the fields of genetics, molecular biology, bioinformatics, cytology, pharmacy and other related technical fields. Among them, 50% of the total number is abundant. R & D covers genetic diseases, drug genomes, tumors, intestinal diseases and so on. At the same time, the team also cooperated in various fields with famous experts, such as Peking Union Medical College Hospital, Department of aspiration, and other well-known experts.
In addition to medical testing services, another important industry direction of medical is the registration, production and sale of medical devices / IVD. At present, the whole industry chain product based on sequencing technology is applied in the detection and analysis of bacterial diversity in intestinal microflora. Including sample preservation solution, DNA extraction kit, DNA library kit, library quantitative equipment, sequencer and so on.
Ovison was awarded the "Tianjin science and technology SMEs" in 2017, and was awarded the national science and technology small and medium-sized enterprise in 2018. 3 software copyrights, 1 invention patents and 2 trademarks have been obtained. 7 other software copyrights have been declared in succession.
Ovison's medicine has been ready to go. We will speed up the speed of the transfer of scientific research, continuously optimize the testing service, effectively help the comprehensive development of the national medicine and the big health industry, and contribute to the health of all people, and make the gene technology truly serve the general public.